Interviews with biopharma leaders and outsourcing partners reveal emerging trends in clinical trial resourcing models, highlighting a shift away from traditional full-service CRO arrangements toward ...

Discover the challenges sites face with eCOA, eConsent, and ePRO platforms and the support needed to reduce technical burdens.

Currently, seven CAR T-cell therapies 1 and six T-cell engager therapies have been approved by the FDA. 2 Despite these advancements and their clear benefits, immunotherapy-based treatments carry ...

Partnerships are also critical. Many small biotechs deploy CROs to assist with trials, and Conga’s platform allows these ...

Tom Cowen, head, healthcare, life sciences, Conga, shares how leading pharmaceutical companies are using Contract Lifecycle ...

Last week’s top stories explored the push for digital-first clinical data systems, why cybersecurity must be central in CRO qualification, and how AI-driven contracting tools are helping sponsors cut ...

Modernizing Clinical Trials: A Site-Centered Roadmap for the Future Simplifying startup, empowering sites through networks, ...

AstraZeneca and Daiichi Sankyo have announced that their supplemental Biologics License Application (sBLA) for Enhertu ...

Paul Shawah, EVP, strategy, Veeva Systems and Richard Staub, president, R&D solutions, IQVIA, explain how their partnership ...

The pharmaceutical industry, with its wealth of sensitive data and critical research, must remain at the forefront of cybersecurity efforts. By integrating cybersecurity considerations into every ...

The FDA has approved Eli Lilly’s Inluriyo (imlunestrant), the first oral estrogen receptor antagonist for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, ...

In this video interview, Ananth Kadambi, VP of real-world evidence and modeling solutions at Certara, discusses how model-informed drug development can help sponsors predict efficacy and safety ...